NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025. SO WHAT: If you purchased Maravai securit ...

SAN DIEGO, March 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, both dates inclusive (the "Class Period"), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit.  Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai as well as ...

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=134617&fr ...

SAN FRANCISCO, March 7, 2025 /PRNewswire/ -- A class action lawsuit has been filed against Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators. The suit, captioned Nelson v. Maravai Lifesciences Holdings, et al., No. 3:25-cv-00499-AGS-AHG (S.D. Cal.), represents investors who purchased Maravai securities between August 7, 2024 and February 24, 2025.Hagens Berman is investigating the alleged claims and urges Maravai investors who ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk ...

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1] Group 1: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint states that Maravai's goodwill was overstated, leading to materially misleading statements about the company's business and prospects [2] Group 2: Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or small group with the largest financial interest [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is encouraging Maravai investors who have suffered significant losses to contact them for more information [4] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise ...

Core Viewpoint - The Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and inadequate internal controls over financial reporting [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Nelson v. Maravai LifeSciences Holdings, Inc., allows purchasers of Maravai securities from August 7, 2024, to February 24, 2025, to seek lead plaintiff status by May 5, 2025 [1][5]. - Allegations include that Maravai made false statements regarding its financial reporting, specifically concerning revenue recognition and the overstatement of goodwill [3][4]. - On February 25, 2025, Maravai announced a delay in its fiscal 2024 earnings release, citing the need for additional time to assess a potential non-cash impairment charge related to goodwill and an error in revenue recognition that affected approximately $3.9 million [4]. Group 2: Financial Impact - Following the announcement of the earnings release delay, Maravai's stock price dropped nearly 22% [4]. - The lawsuit highlights concerns over Maravai's internal controls and the effectiveness of its disclosure procedures as of December 31, 2024 [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, noted for its significant recoveries in securities fraud cases, having secured $6.6 billion for investors in recent years [6].

SAN DIEGO, March 6, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025. Maravai is a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.For more information, submit a form, email attor ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to allegations of violations of federal securities laws, particularly concerning revenue recognition and internal controls [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Maravai and its executives made false or misleading statements and failed to disclose inadequate internal controls over financial reporting related to revenue recognition [4]. - Maravai identified an error in revenue recognition that resulted in approximately $3.9 million being recorded incorrectly, leading to a material weakness in its internal controls [5]. - Following the announcement of these issues, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [6]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses between August 7, 2024, and February 24, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - There is a deadline of May 5, 2025, for investors to seek the role of lead plaintiff in the federal securities class action filed against Maravai [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will direct and oversee the litigation on behalf of the class [7].